AP3225A - New combination between 4-{3-[CIS-hexahydrocyclopenta[C]pyrrol-2(1H)-yl]propoxy}benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it - Google Patents

New combination between 4-{3-[CIS-hexahydrocyclopenta[C]pyrrol-2(1H)-yl]propoxy}benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it

Info

Publication number
AP3225A
AP3225A AP2012006607A AP2012006607A AP3225A AP 3225 A AP3225 A AP 3225A AP 2012006607 A AP2012006607 A AP 2012006607A AP 2012006607 A AP2012006607 A AP 2012006607A AP 3225 A AP3225 A AP 3225A
Authority
AP
ARIPO
Prior art keywords
hexahydrocyclopenta
pyrrol
benzamide
propoxy
cis
Prior art date
Application number
AP2012006607A
Other languages
English (en)
Other versions
AP2012006607A0 (en
Inventor
Caryn Trocme-Thibierge
Aurore Sors
Annette Merdes
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47682151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AP2012006607A0 publication Critical patent/AP2012006607A0/xx
Application granted granted Critical
Publication of AP3225A publication Critical patent/AP3225A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2012006607A 2011-12-09 2012-12-05 New combination between 4-{3-[CIS-hexahydrocyclopenta[C]pyrrol-2(1H)-yl]propoxy}benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it AP3225A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1103777A FR2983732B1 (fr) 2011-12-09 2011-12-09 Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent

Publications (2)

Publication Number Publication Date
AP2012006607A0 AP2012006607A0 (en) 2012-12-31
AP3225A true AP3225A (en) 2015-04-30

Family

ID=47682151

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006607A AP3225A (en) 2011-12-09 2012-12-05 New combination between 4-{3-[CIS-hexahydrocyclopenta[C]pyrrol-2(1H)-yl]propoxy}benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it

Country Status (28)

Country Link
US (2) US8921409B2 (es)
EP (1) EP2601942A1 (es)
JP (1) JP5591310B2 (es)
KR (1) KR101489670B1 (es)
CN (1) CN103157111B (es)
AP (1) AP3225A (es)
AR (1) AR089112A1 (es)
AU (1) AU2012258339A1 (es)
BR (1) BR102012031031A2 (es)
CA (1) CA2798549A1 (es)
CL (1) CL2012003437A1 (es)
CO (2) CO6660080A1 (es)
CR (1) CR20120608A (es)
EA (1) EA201201530A1 (es)
EC (1) ECSP12012329A (es)
FR (1) FR2983732B1 (es)
GT (1) GT201200329A (es)
MA (1) MA34867B1 (es)
MD (1) MD4348B1 (es)
MX (1) MX2012014184A (es)
NI (1) NI201200178A (es)
PE (1) PE20130813A1 (es)
PH (1) PH12012000378A1 (es)
SG (1) SG191494A1 (es)
TN (1) TN2012000563A1 (es)
TW (1) TWI457123B (es)
UY (1) UY34475A (es)
WO (1) WO2013083887A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3003466B1 (fr) * 2013-03-22 2015-08-07 Servier Lab Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques
KR101484405B1 (ko) * 2013-08-14 2015-01-19 서울대학교산학협력단 Ninjurin1 결핍 유래의 강박증 예방 또는 치료용 약학적 조성물
GB201509134D0 (en) 2015-05-28 2015-07-15 Electrophoretics Ltd Biomolecules involved in Alzheimer's disease
US11617734B2 (en) * 2015-07-22 2023-04-04 Anavex Life Sciences Corp. Enantiomers of A2-73, analogues, and sigma agonist activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101458A1 (en) * 2002-05-31 2003-12-11 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
WO2005000216A2 (en) * 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
US7432280B2 (en) * 2003-06-20 2008-10-07 Eli Lilly And Company 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake
US20060020042A1 (en) * 2004-01-05 2006-01-26 Forest Laboratories, Inc. Memantine for the treatment of mild and mild to moderate Alzheimer's disease
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EP1740172A4 (en) * 2004-03-19 2007-10-10 Axonyx Inc ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER
FR2937119B1 (fr) 2008-10-15 2010-12-17 Air Liquide Procede de production d'energie et capture de co2
FR2937251B1 (fr) * 2008-10-16 2011-03-18 Servier Lab Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
FR2953515B1 (fr) * 2009-12-09 2011-12-23 Servier Lab Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
GT201200329A (es) 2014-03-14
US8921409B2 (en) 2014-12-30
PE20130813A1 (es) 2013-07-28
CN103157111B (zh) 2015-02-11
NI201200178A (es) 2013-05-13
JP2013121956A (ja) 2013-06-20
EA201201530A1 (ru) 2013-07-30
BR102012031031A2 (pt) 2013-10-29
SG191494A1 (en) 2013-07-31
AR089112A1 (es) 2014-07-30
AU2012258339A1 (en) 2013-06-27
UY34475A (es) 2013-07-31
CL2012003437A1 (es) 2014-01-24
EP2601942A1 (fr) 2013-06-12
NZ604084A (en) 2014-07-25
CO6660080A1 (es) 2013-04-30
AP2012006607A0 (en) 2012-12-31
MA34867B1 (fr) 2014-02-01
TWI457123B (zh) 2014-10-21
MD4348B1 (ro) 2015-05-31
FR2983732B1 (fr) 2013-11-22
WO2013083887A8 (fr) 2013-08-08
CO6690116A1 (es) 2013-06-17
JP5591310B2 (ja) 2014-09-17
US20130150421A1 (en) 2013-06-13
PH12012000378A1 (en) 2015-09-11
FR2983732A1 (fr) 2013-06-14
KR101489670B1 (ko) 2015-02-04
CN103157111A (zh) 2013-06-19
US20150080448A1 (en) 2015-03-19
CA2798549A1 (fr) 2013-06-09
KR20130065602A (ko) 2013-06-19
TW201334777A (zh) 2013-09-01
MX2012014184A (es) 2013-06-18
TN2012000563A1 (fr) 2014-04-01
ECSP12012329A (es) 2013-01-31
WO2013083887A1 (fr) 2013-06-13
CR20120608A (es) 2014-03-05

Similar Documents

Publication Publication Date Title
IL228506A (en) Opioid receptor ligands and pharmacy preparations containing them
AP3104A (en) New association between 4-{3-[CIS-hexahydrocyclopenta[c]pyrrol-2(1H)-YL]propoxy}benzamide and an Acetylcholinesterase inhibitor, and pharmaceutical compositions containing it
SG11201404030YA (en) P2x4 receptor antagonist
SI2552920T1 (sl) Nove nk-3 receptor selektivne antagonist spojine, farmacevtski sestavki in postopki za uporabo pri nk-3 receptor posredovanih motnjah
PL2627649T3 (pl) Antagoniści receptora CXCR4
SG2014011555A (en) Lysophosphatidic acid receptor antagonists
IL230218A (en) Converted atherothecyclic compounds, their preparations and their pharmaceutical preparations
ZA201207292B (en) Cgrp receptor antagonist
ZA201306744B (en) Antagonists of the interleukin-1 receptor
PT2785692T (pt) Anilinas substituídas como antagonistas do ccr(4)
ZA201305576B (en) Trpm8 receptor antagonists
PT2935227T (pt) Amidas diazol como antagonistas do recetor ccr1
ZA201405959B (en) Novel neurokinin 1 receptor antagonist compounds
EP2617717A4 (en) ANTAGONIST OF P2X4 RECEIVER
AP3225A (en) New combination between 4-{3-[CIS-hexahydrocyclopenta[C]pyrrol-2(1H)-yl]propoxy}benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it
ZA201403245B (en) Process for the preparation of an endothelin receptor antagonist
ZA201204183B (en) Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide hydrochloride and pharmaceutical compositions containing it
IL241743A0 (en) Non-competitive nicotinic receptor antagonists
IL237150B (en) Preparations containing combinations of receptor antagonists and agonists
ZA201303872B (en) Improved process for the preparation of 2-trifluoromethyl-5-(1-substituted)alkylpyridines
FR2976286B1 (fr) 4-{3-[trans-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, son procede de preparation et les compositions pharmaceutiques qui le contiennent
AU2012202328A1 (en) New Association Between 4-{3-[cis-Hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-propoxy}Benzamide and an Acetylcholinesterase inhibitor, and Pharmaceutical Compositions Containing It
IL230334A0 (en) Non-competitive nicotinic receptor antagonists
HK1188437A (en) Nicotinic receptor non-competitive antagonists
HK1187526A (en) Lysophosphatidic acid receptor antagonists and uses thereof